The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
April 26th 2025
New research confirms hydroxyurea's long-term effectiveness in reducing hospital visits for children with sickle cell anemia, supporting its use as standard treatment.
Pharmacist Shoots, Injures Robber Wielding Realistic-Looking Gun
December 9th 2014When a would-be robber entered a pharmacy in Wyoming with what looked like a real gun, a pharmacist behind the counter reached for his firearm and injured the suspect by shooting him, according to the Wyoming Tribune Eagle.
Read More
NovoEight Shown to Reduce Annualized Bleeding Rate Among Patients with Hemophilia A
December 9th 2014Novo Nordisk announced that its phase 3 study of patients with hemophilia A, who had the highest annualized bleeding rates in its previous study, saw the biggest reduction in bleeding over the duration of treatment using turoctocog alfa.
Read More
NACDS Notes Improvements and Remaining Problems in Defense Bill's TRICARE Approach
December 8th 2014As Congress continues consideration of the bipartisan conference agreement to the FY 2015 National Defense Authorization Act National Association of Chain Drug Stores, President and CEO Steven C. Anderson, IOM, CAE issued a statement.
Read More
World TeamTennis and Mylan Announce Title Sponsorship Extension Through 2017
December 8th 2014World TeamTennis, the innovative leader in professional team tennis competition, and Mylan, one of the world's leading pharmaceutical companies, today announced an extension of their title sponsorship agreement through 2017.
Read More
Cardinal Health Launches New Analytics Tool to Help Hospitals Improve Antibiotic Stewardship Efforts
December 8th 2014Cardinal Health today introduced a powerful new tool that gives pharmacists the ability to rapidly analyze antibiotic use trends and identify significant opportunities to improve antibiotic stewardship efforts.
Read More
Survey: Consumers Lack Knowledge of Obamacare Tax Implications
December 8th 2014The upcoming tax season will be the first time Americans face penalties for not having health insurance, but a new survey suggests the public is still very much confused about their responsibilities and options.
Read More
Loeb Receives ASHP Board of Directors Award of Honor
December 8th 2014ASHP today recognized the work of the late Jerod M. Loeb, Ph.D., a tireless patient safety advocate, with the ASHP Board of Directors Award of Honor. Loeb's widow, Sherri, accepted the award during the opening session of ASHP's Midyear Clinical Meeting in Anaheim, CA. Dr. Loeb passed away in 2013 from metastatic prostate cancer.
Read More
Kienle Receives ASHP Award for Distinguished Practice Leadership
December 8th 2014ASHP today honored Patricia Clancy Kienle, R.Ph., M.P.A., FASHP, with its Board of Directors Award for Distinguished Leadership in Pharmacy Practice during the opening session of the association's 49th Midyear Clinical Meeting in Anaheim, CA.
Read More
Cold and Flu Meds Pose Risks For High Blood Pressure
December 8th 2014If you have high blood pressure and purchase an over-the-counter medication, you may be getting more than you bargained for. That's the word from experts who caution that some medications taken over the counter can have a negative impact on blood pressure. If patients are unknowingly taking medications that elevate blood pressure, it could undermine efforts to keep blood pressure in a safe range.
Read More
Mild Coronary Artery Disease Puts Diabetics at Cardiovascular Risk
December 8th 2014New study results dispute the belief that diabetic patients with mild or non-obstructive coronary artery disease have a lower risk of major adverse cardiovascular events and death than their counterparts with obstructive disease.
Read More
Astellas Announces End of License Agreement with Janssen to Develop and Commercialize ASP015K
December 7th 2014Astellas Pharma, Inc, announced that its license agreement with Janssen Biotech, Inc, to develop and commercialize ASP015K, Astellas' oral Janus Kinase inhibitor, will end effective January 15, 2015.
Read More